MGMT mRNA Expression and Glioma Outcomes
Author Information
Author(s): Simone Kreth, Niklas Thon, Sabina Eigenbrod, Juergen Lutz, Carola Ledderose, Rupert Egensperger, Joerg C. Tonn, Hans A. Kretzschmar, Ludwig C. Hinske, Friedrich W. Kreth
Primary Institution: Ludwig Maximilians University, Munich, Germany
Hypothesis
Does MGMT mRNA expression have prognostic significance independent of MGMT promoter methylation in malignant glioma patients?
Conclusion
MGMT mRNA expression is a significant predictor of treatment response and survival in malignant glioma patients, independent of MGMT promoter methylation status.
Supporting Evidence
- Low MGMT mRNA expression was strongly predictive for prolonged time to progression.
- MGMT promoter methylation status was highly correlated with MGMT mRNA expression.
- Discordant findings were observed in 19% of patients, indicating complex regulation of MGMT expression.
Takeaway
This study found that how much MGMT mRNA is present in brain tumors can help doctors predict how well patients will respond to treatment, even if the tumor's DNA is changed in a certain way.
Methodology
The study included adult patients with malignant glioma, analyzed MGMT promoter methylation and mRNA expression using PCR and sequencing, and assessed clinical outcomes through statistical models.
Potential Biases
Potential bias in patient selection and treatment assignment could affect the results.
Limitations
The study may not account for all potential confounding factors influencing treatment response and survival.
Participant Demographics
63 patients (33 men, 30 women) with a median age of 59 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
0.11–0.46
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website